期刊
JOURNAL OF CLINICAL ONCOLOGY
卷 28, 期 35, 页码 5219-5227出版社
AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2009.27.4944
关键词
-
类别
资金
- National Cancer Institute [R21CA126674]
- Starr Cancer Consortium
- Dana-Farber Cancer Institute
Cancer is a disease of the genome. Most tumors harbor a constellation of structural genomic alterations that may dictate their clinical behavior and treatment response. Whereas elucidating the nature and importance of these genomic alterations has been the goal of cancer biologists for several decades, ongoing global genome characterization efforts are revolutionizing both tumor biology and the optimal paradigm for cancer treatment at an unprecedented scope. The pace of advance has been empowered, in large part, through disruptive technological innovations that render complete cancer genome characterization feasible on a large scale. This article highlights cardinal biologic and clinical insights gleaned from systematic cancer genome characterization. We also discuss how the convergence of cancer genome biology, technology, and targeted therapeutics articulates a cohesive framework for the advent of personalized cancer medicine.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据